Paediatric Hematology and Oncology
Today almost 80% of all children with cancer are cured. This is a result of both international clinical studies on cancer therapy, in which treatments are carefully evaluated, and laboratory studies resulting in novel therapies.
Paediatric Hematology/Oncology Research
Similarly, the outcome in many non-malignant hematological disorders have improved markedly. The Childhood Cancer Research Unit works actively in both clinical and laboratory studies. In addition, we also perform care and psychosocial research with the aim to improve the care of affected children and their families.
The most common cancer forms are leukemias and brain tumours, which comprise one third of all cancers each, while one third suffers from other forms of tumours.
The treatment of children with cancer has improved successfully, and currently almost 80% of all children are cured. Nevertheless, childhood cancer is still the most common death cause of death in children between 1 and 14 years of age, followed in frequency by deaths caused by accidents.
In the context of Orphan Drugs, the Medical Products Agency (MPA) adheres to the European Orphan Drug Regulation definition of a prevalence of below 1 in 2000 individuals. However, the knowledge database of the Swedish National Board of Health and Welfare defines rare diseases as "Disorders or injuries resulting in extensive handicaps and affecting no more than 100 individuals in one million inhabitants".
The number of rare diseases is estimated to 5-8000 and 6-8 % of the European population are believed to be affected by a rare disease during their lifetime. Six percent of the Swedish population is about 540 000 individuals, which means that, taken together, rare diseases are not rare. Read more about rare diseases